Theriva Biologics Files 8-K: Name Changes & Financials
Ticker: TOVX · Form: 8-K · Filed: Oct 16, 2024 · CIK: 894158
| Field | Detail |
|---|---|
| Company | Theriva Biologics, Inc. (TOVX) |
| Form Type | 8-K |
| Filed Date | Oct 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-history, disclosure, financials
TL;DR
Theriva Biologics (formerly Synthetic Biologics) filed an 8-K on Oct 16, 2024, covering disclosures and financials.
AI Summary
On October 16, 2024, Theriva Biologics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, along with Financial Statements and Exhibits. Theriva Biologics, Inc. was formerly known as Synthetic Biologics, Inc., Adeona Pharmaceuticals, Inc., and PipEx Pharmaceuticals, Inc., with name changes occurring on March 5, 2012, October 27, 2008, and December 14, 2006, respectively.
Why It Matters
This filing provides an update on Theriva Biologics' corporate history and regulatory disclosures, which is important for investors tracking the company's evolution and compliance.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting historical corporate information and standard disclosures, not indicating immediate operational or financial distress.
Key Players & Entities
- Theriva Biologics, Inc. (company) — Registrant
- Synthetic Biologics, Inc. (company) — Former Company Name
- Adeona Pharmaceuticals, Inc. (company) — Former Company Name
- PipEx Pharmaceuticals, Inc. (company) — Former Company Name
- October 16, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing by Theriva Biologics, Inc.?
The filing serves as a Current Report on Form 8-K, primarily covering Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits, with the earliest event reported on October 16, 2024.
What were Theriva Biologics, Inc.'s previous names?
Theriva Biologics, Inc. was formerly known as Synthetic Biologics, Inc., Adeona Pharmaceuticals, Inc., and PipEx Pharmaceuticals, Inc.
When did the name changes for Theriva Biologics occur?
The name changes occurred on March 5, 2012 (from Synthetic Biologics, Inc.), October 27, 2008 (from Adeona Pharmaceuticals, Inc.), and December 14, 2006 (from PipEx Pharmaceuticals, Inc.).
In which state is Theriva Biologics, Inc. incorporated?
Theriva Biologics, Inc. is incorporated in Nevada.
What is the business address of Theriva Biologics, Inc.?
The business address is 9605 Medical Center Drive, Suite 270, Rockville, MD 20850.
Filing Stats: 645 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2024-10-16 08:10:19
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TOVX NYSE American Indica
Filing Documents
- tm2426230d1_8k.htm (8-K) — 26KB
- tm2426230d1_ex99-1.htm (EX-99.1) — 14KB
- tm2426230d1_ex99-1img01.jpg (GRAPHIC) — 5KB
- 0001104659-24-108958.txt ( ) — 223KB
- syn-20241016.xsd (EX-101.SCH) — 3KB
- syn-20241016_lab.xml (EX-101.LAB) — 33KB
- syn-20241016_pre.xml (EX-101.PRE) — 22KB
- tm2426230d1_8k_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On October 16, 2024, Theriva Biologics, Inc. (the "Company") issued a press release announcing that the European Commission has adopted the European Medicines Agency ("EMA") recommendation to grant orphan medicinal product designation to lead clinical candidate VCN-01, the Company's systemic, selective, stroma-degrading oncolytic adenovirus, for the treatment of retinoblastoma . The information in this Item 7.01 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The press release furnished as Exhibit 99.1 to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are "forward-looking" rather than historical.
01. Other Events
Item 8.01. Other Events. On October 16, 2024, the Company issued a press release announcing that the European Commission has adopted the EMA recommendation to grant orphan medicinal product designation to lead clinical candidate VCN-01, the Company's systemic, selective, stroma-degrading oncolytic adenovirus, for the treatment of retinoblastoma .
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release issued by Theriva Biologics, Inc., dated October 16, 2024 104 Cover Page Interactive Data File (embedded within the XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 16, 2024 THERIVA BIOLOGICS, INC. By: /s/ Steven A. Shallcross Name: Steven A. Shallcross Title: Chief Executive Officer and Chief Financial Officer